Navigation Links
URL Pharma Expands Colcrys(R) Patient Assistance Program
Date:3/15/2010

PHILADELPHIA, March 15 /PRNewswire/ -- URL Pharma, Inc. today announced the launch of an expanded Colcrys® (colchicine, USP) Patient Assistance Program (PAP) that significantly increases the number of patients eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes of up to 6 times the federal poverty level are eligible for the new Colcrys PAP. This expanded program is available to patients immediately.

Colcrys is indicated for the prevention and treatment of gout flares and for the treatment of Familial Mediterranean Fever (FMF).

The expanded Colcrys PAP covers eligible patients as follows:

  • Uninsured or Medicare Part D patients with household incomes up to 4 times the federal poverty level (up to $88,000 per year for a family of four) may obtain Colcrys for $5 per month

  • Uninsured or Medicare Part D patients with household incomes between 4-6 times the poverty level (up to $132,000 per year for a family of four) may obtain Colcrys for $25 per month

"URL Pharma is committed to making Colcrys therapy available to all who need it. We have worked closely with physicians and patients to ensure this program meets the needs of those with gout and FMF, and we are proud that our program is among the most generous patient assistance programs ever offered by any pharmaceutical company," said Richard H. Roberts, M.D., Ph.D., President, CEO and Chairman, URL Pharma. "Patients can now be assured of receiving an FDA-approved colchicine that meets all modern standards of safety, efficacy, purity and consistency, with no financial barriers to access."

Patients can learn more and sign up for the expanded Colcrys PAP by visiting www.needymeds.org or www.colcrys.com, or by calling 1-888-811-8423 from 8:00 am to 6:00 pm Eastern Time, Monday through Friday. Patients not eligible for the expanded PAP but who still need help in paying for Colcrys are also encouraged to call the toll-free number to determine if additional assistance may be available for them.

The program is open to all U.S. residents with a valid Colcrys prescription who meet the income eligibility requirements and who are uninsured or covered only by Medicare Part D.  Verification of household income will be required as part of the application process. Patients will be asked to attest that they will not claim co-payments on any Medicare plan.  Patients are eligible to receive Colcrys through the program for a period of one year from the date of initial enrollment, and will need to reapply to the program annually.

Important Safety Information

Colcrys® (colchicine, USP) tablets are indicated for the prophylaxis and treatment of acute gout flares and Familial Mediterranean Fever (FMF).

Colcrys is contraindicated in patients with renal or hepatic impairment who are concurrently prescribed P-gp inhibitors or strong inhibitors of CYP3A4 as life-threatening or fatal toxicity has been reported. In a controlled clinical trial, the most common adverse events reported were diarrhea and pharyngolaryngeal pain. Rarely, myelosuppression, thrombocytopenia, and leukopenia have been reported in patients taking colchicine. Rhabdomyolysis has been occasionally observed, especially when colchicine is prescribed in combination with other drugs known to cause this effect. Monitoring is recommended under these conditions.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

You may also report negative side effects to the manufacturer of Colcrys by calling 1-888-351-3786. Please see www.colcrys.com for full prescribing information.

About URL Pharma

URL Pharma, Inc., headquartered in Philadelphia, PA, is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. After a long history of generic pharmaceutical research, development, and manufacturing, the Company has successfully transitioned to a technology-driven, specialty pharmaceutical business. The Company seeks to develop and commercialize scientifically and medically innovative products that address unmet medical needs for improvements in safety and efficacy. For more information, visit www.urlpharma.com.

For further information, please call 215-697-1900 or e-mail us at media@urlpharma.com.

SOURCE URL Pharma, Inc.

Back to top

RELATED LINKS
http://www.urlpharma.com

'/>"/>

SOURCE URL Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CT Corsearch Announces Trademark Search Capabilities for the U.S. Pharmaceutical Market
2. Poniard Pharmaceuticals Announces $6.3 Million Financing
3. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
4. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
5. Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer
6. SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies
7. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
8. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R)
9. Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
11. U.S. Surgeon General Dr. Regina M. Benjamin to Deliver Commencement Address at Albany College of Pharmacy and Health Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... service members that have been wounded in battle and their families. Venture Construction Group ...
Breaking Medicine News(10 mins):